Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

炎症性腸疾患(IBD) 治療薬の世界市場

◆タイトル:Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028
◆商品コード:VGN808052
◆調査・発行会社:visiongain
◆発行日:2018年5月
◆ページ数:196
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥399,452見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、炎症性腸疾患(IBD) 治療薬の世界市場について調査・分析し、炎症性腸疾患(IBD) 治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 196-page report you will receive 141 charts– all unavailable elsewhere.

The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

• Submarket forecasts from 2018-2028:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

• Revenue forecast from 2018-2028 for 17 leading products:
• Humira
• Remicade
• Lialda
• Asacol
• Pentasa
• Xifaxan
• Cimzia
• Tysabri
• Simponi
• Canasa/Salofalk
• Entyvio
• Apriso
• Medrol
• Neoral
• Entocort
• Uceris
• Azulfidine

• Revenue forecasts from 2018-2028 for 11 countries:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

【レポートの目次】

1. Report Overview

1.1 World IBD Drugs Market: Overview of Findings

1.2 Why You Should Read This Report

1.3 How the Study Delivers

1.4 Main Questions Covered in the Analysis

1.5 Who is this Report For?

1.6 Methods of Research and Analysis

1.6.1 Primary Research

1.6.2 Secondary Research

1.6.3 Market Evaluation and Forecasting Methods

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Reports

1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market

2.1 What is Inflammatory Bowel Disease (IBD)?

2.2 Classification of IBD

2.3 Symptoms and Diagnosis of IBD

2.4 Multifactorial Causes of IBD

2.5 How Common is IBD?

2.6 What Are the Treatment Options for IBD?

2.6.1 Aminosalicylates – The Most Common Therapy

2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?

2.6.3 Corticosteroids – Uptake from Uceris?

2.6.4 Immunomodulators – Slow to Act?

2.6.5 Monoclonal Antibodies – Not Cost-effective?

2.7 Treatment Goals for IBD – Treat-to-Target Approach?

2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Drug Market, 2018-2028

3.1 The Inflammatory Bowel Disease Market in 2016 and 2017

3.2 Forecast 2018-2028: Impacted by Biosimilars?

3.3 Biologic Therapies Forecast 2018-2028 – Driving the Market

3.4 Aminosalicylates Forecast 2018-2028: The steady decline

3.5 Antibiotics Forecast 2018-2028: Growing Despite Challenges

3.6 Corticosteroids Forecast 2018-2028: Driven by Uceris

3.7 Immunomodulators Forecast 2018-2028 – Will Slowly Lose Market Share

4. Market Prospects for Leading IBD Drugs, 2018-2028

4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period

4.1.1 Humira: Forecast and Analysis, 2018-2028

4.2 Remicade (Janssen Biotech) – Will Slowly Be Eroded by Biosimilars

4.2.1 Remicade: Forecast and Analysis, 2018-2028

4.3 Asacol (Allergan) – Threat from Generic Competition

4.3.1 Asacol: Forecast and Analysis, 2018-2028

4.4 Pentasa (Shire) – Differentiated by Its Delivery System

4.4.1 Pentasa: Forecast and Analysis, 2018-2028

4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?

4.5.1 Lialda: Forecast and Analysis, 2018-2028

4.6 Tysabri (Perrigo) – Still Protected by Patent

4.6.1 Tysabri: Forecast and Analysis, 2018-2028

4.7 Xifaxan (Valeant) – Still Growing Significantly

4.7.1 Xifaxan: Forecast and Analysis, 2018-2028

4.8 Cimzia (UCB) – How Will It Fare Against Biosimilars?

4.8.1 Cimzia: Forecast and Analysis, 2018-2028

4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?

4.9.1 Entocort: Forecast and Analysis, 2018-2028

4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?

4.10.1 Neoral: Forecast and Analysis, 2018-2028

4.11 Medrol (Pfizer) – Another Leading Steroid

4.11.1 Medrol: Forecast and Analysis, 2018-2028

4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?

4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027

4.13 Apriso (Valeant) – Challenger to Asacol?

4.13.1 Apriso: Forecast and Analysis, 2018-2028

4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market

4.14.1 Azulfidine: Forecast and Analysis, 2018-2028

4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment

4.15.1 Entyvio: Forecast and Analysis, 2018-2028

4.16 Simponi (Janssen Biotech) – Rising Star for the Market?

4.16.1 Simponi: Forecast and Analysis, 2018-2028

4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System

4.17.1 Uceris: Forecast and Analysis, 2018-2028

5. Leading National Markets: Sales Outlooks, 2017-2027

5.1 IBD Drugs – Leading National Markets 2017

5.2 The US IBD Drug Market, 2018-2028 – The World Leader

5.3 The Japanese IBD Drug Market, 2018-2028 – Growing Significantly?

5.4 The EU-5 IBD Drug Market, 2018-2028 – Driven by the UK

5.4.1 The German IBD Drug Market, 2018-2028

5.4.2 The French IBD Drug Market, 2018-2028

5.4.3 The UK IBD Drug Market, 2017-2027

5.4.4 The Spanish IBD Drug Market, 2017-2027

5.4.5 The Italian IBD Drug Market, 2018-2028

5.5 IBD Drug Markets in BRIC Countries – Taking More Market Share

5.5.1 The Brazilian IBD Drug Market, 2018-2028

5.5.2 The Russian IBD Drug Market, 2018-2028

5.5.3 The Indian Drug Market, 2018-2028

5.5.4 The Chinese IBD Drug Market, 2018-2028

6. The R&D Pipeline for Inflammatory Bowel Disease, 2017

6.1 Top Marketed and pipeline products – Launch dates and Patent expiry

6.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation

6.2.1 CyCol (Sigmoid Pharma)

6.2.2 PF-04236921 (Pfizer)

6.2.3 QAX 576 (Novartis)

6.2.4 TNF Kinoid (Neovacs)

6.2.5 Vidofludimus (4SC) – Suspended

6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)

6.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue

6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)

6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)

6.3.3 MEDI 7183/AMG 181 (AstraZeneca)

6.3.4 Etrolizumab (Roche)

6.3.5 PF-00547659 (Pfizer)

6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)

6.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)

6.4 TNF-α Inhibitors – a Specific Target

6.4.1 AVX-470 (Avaxia Biologics)

6.4.2 Ozoralizumab (ALX-0061, Ablynx)

6.5 Stem Cell Therapies – Basis for a Cure?

6.5.1 Ovasave (TxCell)

6.5.2 MultiStem (Athersys and Pfizer)

6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)

6.5.4 Cx601 (TiGenix)

6.6 JAK Inhibitors – New Target Pathway

6.6.1 JNJ-54781532 (Janssen)

6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)

6.7 Toll-like Receptor Agonists

6.7.1 BL-7040 (BioLineRX)

6.7.2 Kappaproct (InDex Pharmaceuticals)

6.8 Other Classes of Agent

6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)

6.8.2 GLPG0974 (Galapagos)

6.8.3 RPC1063 (Receptos/now Celgene)

6.8.4 SGX203 (Soligenix)

6.8.5 Mongersen (GED-0301, Celgene)

6.8.6 Tetomilast (OPC-6535, Otsuka)

6.8.7 Laquinimod (Active Biotech)

6.8.8 RHB-104 (RedHill Biopharma)

6.8.9 Ozanimod (Celgene)

6.8.10 GED-0301 (Celgene)

6.9 Biosimilar Candidates – Promising Competitors of Leading Biologics

6.9.1 Adalimumab Biosimilars

6.9.2 Infliximab Biosimilars

7. Qualitative Analysis of the Inflammatory Bowel Disease Drug Industry and Market, 2017

7.1 SWOT and STEP Analysis of the IBD Drugs Market

7.2 What Factors Will Stimulate the IBD Market?

7.2.1 Increasing Disease Incidence in Most National Markets

7.2.2 Better Diagnosis – Early Referrals

7.2.3 Delivery Systems Improve Existing Drugs

7.2.4 Biological Drugs – Driving the Market Significantly

7.2.5 Socioeconomic Costs of IBD

7.3 What Factors Will Restrain the Market?

7.3.1 Lack of Understanding of Disease Aetiology

7.3.2 Compliance – Frequent Dosing is Inconvenient

7.3.3 Limitations of Biologics – Side Effect Profiles

7.3.4 The Possible Development of Alternative Treatments

7.3.5 Surgery – Treatment for Recalcitrant IBD

7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Pharmaceuticals Market, 2017

8.1 The Largest Companies by Revenue

8.1.1 AbbVie

8.1.2 Janssen Biotech

8.1.3 Allergan

8.1.4 Shire Pharmaceuticals

8.1.5 Takeda Pharmaceuticals


9. Conclusions of the Study

9.1 The IBD Drugs Market Will Expand from 2018 to 2028

9.2 Aminosalicylates and Other Non-Biologic Treatments

9.3 Biological Treatments Dominate the Market

9.4 Improvements Needed in IBD Therapy

9.5 Future IBD Treatments: R&D Efforts Look Promising

9.6 The IBD Sector: Looking to the Future with Confidence


Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form


List of Tables

Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis

Table 2.2 Worldwide Prevalence Rates for IBD, 2016

Table 2.3 Worldwide Incidence Rates for IBD, 2016

Table 2.4 Geographical Variations in the Incidence of IBD, 2016

Table 2.5 Other Drug Types Used to Treat IBD, 2016

Table 2.6 Treatment Protocol for IBD, 2016

Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2016 and 2017

Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.4 Global IBD Drug Market Drivers and Restraints 2018-2028

Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.6 Global Biologic Therapies Drivers and Restraints, 2018-2028

Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.8 Global Aminosalicylates Drivers and Restraints, 2018-2028

Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.10 Global Antibiotics Drivers and Restraints, 2018-2028

Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.12 Global Corticosteroids Drivers and Restraints, 2018-2028

Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 3.14 Global Immunomodulators Drivers and Restraints, 2018-2028

Table 4.1 Leading IBD Treatments by Revenue ($m), 2017

Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2018-2028

Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.4 Drivers and Restraints for Humira, 2018-2028

Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.6 Drivers and Restraints for Remicade, 2018-2028

Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.8 Drivers and Restraints for Asacol, 2018-2028

Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.10 Drivers and Restraints for Pentasa, 2018-2028

Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.12 Drivers and Restraints for Lialda, 2018-2028

Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.14 Drivers and Restraints for Tysabri, 2018-2028

Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.16 Drivers and Restraints for Xifaxan, 2018-2028

Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.18 Drivers and Restraints for Cimzia, 2018-2028

Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.20 Drivers and Restraints for Entocort, 2018-2028

Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.22 Drivers and Restraints for Neoral, 2018-2028

Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.24 Drivers and Restraints for Medrol, 2018-2028

Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.26 Drivers and Restraints for Canasa, 2018-2028

Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.28 Drivers and Restraints for Apriso, 2018-2028

Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.30 Drivers and Restraints for Azulfidine, 2018-2028

Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.32 Drivers and Restraints for Entyvio, 2018-2028

Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.34 Drivers and Restraints for Simponi, 2018-2028

Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 4.36 Drivers and Restraints for Uceris, 2018-2028

Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2017

Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2023-2028

Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2023-2027

Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2028

Table 6.1 Key Patent dates for marketed and pipeline products

Table 6.2 Selected IL Inhibitors in Clinical Development, 2018

Table 6.3 Selected CAM Inhibitors in Clinical Development, 2018

Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2018

Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2018

Table 6.6 Selected JAK Inhibitors in Clinical Development, 2018

Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2018

Table 6.8 Selected Other Classes in Clinical Development, 2018

Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market

Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market

Table 8.1 AbbVie Revenues ($m) and Market Share (%), 2017

Table 8.2 Janssen Biotech Revenues ($m) and Market Share (%), 2017

Table 8.3 Allergan Revenues ($m) and Market Share (%), 2017

Table 8.4 Shire Revenues ($m) and Market Share (%), 2017

Table 8.5 Takeda Revenues ($m) and Market Share (%), 2017

Table 9.1 Global IBD Revenue Forecasts ($m), Market Share (%) by Product Category, 2018, 2023, 2028

Table 9.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2018, 2023, 2028

Table 9.3 Summary of IBD Market Drivers and Restraints, 2018-2028


List of Figures

Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2017

Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2018

Figure 3.2 Global IBD Drug Market Forecast ($m), 2018-2028

Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2028

Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2018-2028

Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2018-2028

Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2018-2028

Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2018-2028

Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2018-2028

Figure 4.1 World Humira Revenue Forecast ($m), 2018-2028

Figure 4.2 World Remicade Forecast ($m), 2018-2028

Figure 4.3 World Asacol Forecast ($m), 2018-2028

Figure 4.4 World Pentasa Forecast ($m), 2018-2028

Figure 4.5 World Lialda Forecast ($m), 2018-2028

Figure 4.6 World Tysabri Forecast ($m), 2018-2028

Figure 4.7 World Xifaxan Forecast ($m), 2018-2028

Figure 4.8 World Cimzia Forecast ($m), 2018-2028

Figure 4.9 World Entocort Forecast ($m), 2018-2028

Figure 4.10 World Neoral Forecast ($m), 2018-2028

Figure 4.11 World Medrol Forecast ($m), 2018-2028

Figure 4.12 World Canasa Forecast ($m), 2018-2028

Figure 4.13 World Apriso Forecast ($m), 2018-2028

Figure 4.14 World Azulfidine Forecast ($m), 2018-2028

Figure 4.15 World Entyvio Forecast ($m), 2018-2028

Figure 4.16 World Simponi Forecast ($m), 2018-2028

Figure 4.17 World Uceris Forecast ($m), 2018-2028

Figure 5.1 Global IBD Drug Market by Leading Country (%), 2018

Figure 5.2 Global IBD Drug Market by Leading Country (%), 2028

Figure 5.3 US IBD Drug Market Forecast ($m), 2018-2028

Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2018-2028

Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2018-2028

Figure 5.6 German IBD Drug Market Forecast ($m), 2018-2028

Figure 5.7 French IBD Drug Market Forecast ($m), 2018-2028

Figure 5.8 UK IBD Drug Market Forecast ($m), 2018-2028

Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2018-2028

Figure 5.10 Italian IBD Drug Market Forecast ($m), 2018-2028

Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2018-2028

Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2018-2028

Figure 5.13 Russian IBD Drug Market Forecast ($m), 2018-2028

Figure 5.14 Indian IBD Drug Market Forecast ($m), 2018-2028

Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2018-2028

Figure 8.1 AbbVie Assets – Marketed and Pipeline 2016

Figure 8.2 AbbVie Deals and Partnerships 2011 - 2016

Figure 8.3 Janssen Assets – Marketed and Pipeline 2016

Figure 8.4 Janssen – Deals and Partnerships 2011 - 2016

Figure 8.5 Allergan Assets – Marketed and Pipeline 2016

Figure 8.6 Allergan – Deals and Partnerships 2011 - 2016

Figure 8.7 Shire Assets – Marketed and Pipeline 2016

Figure 8.8 Shire – Deals and Partnerships 2011 - 2016

Figure 8.9 Takeda Assets – Marketed and Pipeline 2016

Figure 8.10 Shire – Deals and Partnerships 2011 - 2015

★調査レポート[炎症性腸疾患(IBD) 治療薬の世界市場] ( Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028 / VGN808052) 販売に関する免責事項
[炎症性腸疾患(IBD) 治療薬の世界市場] ( Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028 / VGN808052) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆